Gyre Therapeutics (GYRE) Change in Receivables (2012 - 2026)
Gyre Therapeutics (GYRE) reported Change in Receivables of -$8.6 million for Q1 2026, down 1287.4% year-over-year from $722000.0 in Q1 2025, and down 277.68% quarter-over-quarter from $4.8 million in Q4 2025.
Gyre Therapeutics (GYRE) Change in Receivables (2012 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has 13 years of Change in Receivables data on file, last reported at -$8.6 million in Q1 2026.
- Change in Receivables for Q1 2026 came in at -$8.6 million, down 1287.4% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.9 million (down 590.86% YoY), and the FY2025 annual result was $10.8 million, up 105.55% from the prior year.
- Change in Receivables eased to -$8.6 million in Q1 2026 per GYRE's latest filing, from $4.8 million in the prior quarter.
- Over five years, Change in Receivables peaked at $4.8 million in Q4 2025 and troughed at -$8.6 million in Q1 2026.
- A 5-year average of -$711857.1 and a median of -$564000.0 in 2022 frame the typical range for Change in Receivables.
- The sharpest annual moves came in 2025 and 2026: Change in Receivables jumped 321.03% in 2025, then sank 1287.4% in 2026.
- A 5-year view of Change in Receivables shows it stood at -$564000.0 in 2022, then plunged by 163.3% to -$1.5 million in 2023, then soared by 177.17% to $1.1 million in 2024, then surged by 321.03% to $4.8 million in 2025, then slumped by 277.68% to -$8.6 million in 2026.
- Business Quant data shows GYRE's Change in Receivables at -$8.6 million in Q1 2026, $4.8 million in Q4 2025, and $722000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -4.08 Mn |
| 10 | Gyre Therapeutics | 554.75 Mn | 540.62 Mn | 8.38 Mn | -8.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.57 Mn |
| Mar 31, 2026 | -8.57 Mn |
| Dec 31, 2025 | 4.83 Mn |
| Dec 31, 2025 | 4.83 Mn |
| Mar 31, 2025 | 722,000.00 |
| Mar 31, 2025 | 722,000.00 |
| Dec 31, 2024 | 1.15 Mn |
| Dec 31, 2024 | 1.15 Mn |
| Dec 31, 2023 | -1.49 Mn |
| Dec 31, 2023 | -1.49 Mn |
| Jun 30, 2022 | -564,000.00 |
| Jun 30, 2022 | -564,000.00 |
| Mar 31, 2022 | -1.05 Mn |
| Mar 31, 2022 | -1.05 Mn |
| Dec 31, 2021 | 704,000.00 |
| Dec 31, 2021 | 704,000.00 |
| Sep 30, 2021 | -857,000.00 |
| Sep 30, 2021 | -857,000.00 |
| Jun 30, 2021 | 965,000.00 |
| Jun 30, 2021 | 965,000.00 |